drugset / Trial / NCT02633813

BE Study of Naftifine HCL

NCT02633813

Phase 3 Completed 693 enrolled Genzum Life Sciences
RandomizedParallel-groupDouble-blindTreatment

Summary

The current study was randomized, double blind, placebo-controlled, prospective, multicenter, comparative therapeutic equivalence study. The study duration for each patient was 6 weeks: Following were the visit details. V1-Baseline and Randomization Visit (Day 1). V2- End of therapy visit (at the end of week 2 + 2 days). V3- Follow up visit (at the end of week 4 + 2 days). V4 - Test of cure visit ( at the end of week 6 + 4 days).

Timeline

Start
2015-03
Primary completion
2015-11
Completion
2015-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Naftifine Other / unclassified 2 % Topical

Indications